Automatically selected top health news story of the day ( ? )
Follow us with Twitter - Facebook - RSS feed - Bookmark
Next update in hours

First RNAi Therapy Approved by FDA

The Scientist - Fri 10 Aug 18

Alnylam's patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis.

The first gene-silencing drug wins FDA approval

ScienceNews - Fri 10 Aug 18

The FDA just approved the first drug that works via RNA interference.

Alnylam's gene silencing drug wins FDA approval

Reuters - Fri 10 Aug 18

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing ...

Patisiran Wins Two Firsts With FDA Approval

MedPageToday - Fri 10 Aug 18

(MedPage Today) -- RNAi drug OK'd to treat polyneuropathy from hereditary transthyretin amyloidosis